Amicogen is showing strong performance. This is interpreted as being influenced by the analysis that the U.S. Biosecurity Act will be strengthened.
As of 1:37 PM on the 5th, Amicogen is trading at 5,690 KRW, up 6.36% compared to the previous day.
According to the industry, the U.S. Biosecurity Act mainly aims to prevent patient data and taxes from falling into the hands of Chinese biotech companies.
However, with the Biosecurity Act being excluded from the current National Defense Authorization Act, concerns have arisen in the market that lobbying by the Chinese government and industry officials may have been effective. Nonetheless, the domestic CDMO and CRO industries mostly hold the view that the U.S. Biosecurity Act will rather be strengthened. It is analyzed that the scope of biosecurity regulations within the U.S. is expected to be expanded.
There is also a forecast that the Biosecurity Act will be passed by the end of the year at the latest. From the U.S. perspective, since it is an important matter for public health, national security, and securing supply chains, it is analyzed that the Biosecurity Act will be legislated no later than this year.
Meanwhile, Amicogen, a pharmaceutical special enzyme development company, is known to be commercializing resin and media, key raw materials for biopharmaceuticals that have depended on foreign imports since this year. In the biopharmaceutical manufacturing process, 'media' serves as the nutrient for cell culture, and 'resin' is used to separate proteins from cultured cells and purify viruses and impurities. Amicogen has secured these through its own technology and is preparing for large-scale supply with the completion of its own production plant.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
